NCT00491764View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Onychomycosis
Interventions
DRUG

SCH 56592

Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.

DRUG

SCH 56592

Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.

DRUG

SCH 56592

Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.

DRUG

SCH 56592

Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.

DRUG

Terbinafine

Terbinafine 250 mg QD for 12 weeks.

DRUG

Placebo

Placebo for 24 weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00491764 - A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) | Biotech Hunter | Biotech Hunter